BioMarin Pharmaceutical Inc.
NASDAQ:BMRNBiotechnology
-$0.10 today
- Market cap
- $11.90B
- Beta
- 0.24
- P/E (TTM)
- 39.4
- EPS (TTM)
- $1.40
Volume 3.07M
Average 2.04M
BMRN Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
BioMarin Pharmaceutical Inc.NASDAQ: BMRN
Income Tax Expense · Q3 FY2026 · quarter ended Sep 2026
Income tax expense turns negative
Q3 FY2026 income tax expense was -$8.94B, compared with $4.42M a year earlier. Trailing-twelve-month income tax expense was -$8.87B. Over 3 fiscal years it compounded at +155.4% a year.
Context
- Income tax expense amounted to 4.1% of revenue in FY2025, up 0.1 pp from a year earlier.
- Income tax expense increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income tax expense holds near -$8.94B or moves back toward the trailing-twelve-month quarterly average of -$2.22B.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 133.58M USD
- Year-over-year change
- +16.3%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 133.58M | +16.3% |
| FY2024 | 2024-12-31 | 114.9M | +449.3% |
| FY2023 | 2023-12-31 | 20.92M | +161.0% |
| FY2022 | 2022-12-31 | 8.02M | +171.1% |
| FY2021 | 2021-12-31 | (11.27M) | — |
Income Tax Expense vs competitors
How BMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5681.4% is the 10th highest of 11, against a peer median of +17.8%.
- Income tax expense amounts to 0.9% of revenue for BMRN, versus a peer median of 0.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $783.2M USD | +1.2% | -8.8% | 6.0% | |
| LTM Mar 2026 | $7.7M USD | -27.6% | +98.9% | 2.1% | |
| LTM Sep 2026 | $6.49M USD | +129940.0% | +46.7% | 1.0% | |
| LTM Jun 2026 | $6.21M USD | +39.9% | +53.7% | 0.5% | |
| LTM Mar 2026 | $3.82M USD | +55.8% | -11.1% | 0.6% | |
| LTM Sep 2026 | -$187K USD | +92.1% | -56.0% | 0.0% | |
| LTM Jun 2026 | -$1.55M USD | -147.5% | — | 0.2% | |
| LTM Jun 2026 | -$28.69M USD | -177.7% | — | 2.8% | |
| LTM Jun 2026 | -$39.75M USD | +34.3% | +31.2% | 0.8% | |
| LTM Sep 2026 | -€619.19M EUR | -6542.6% | +40.1% | 51.2% | |
| LTM Sep 2026 | -$8.87B USD | -5681.4% | +155.4% | 0.9% | |
| Peer median (excluding BMRN) | — | +17.8% | +35.6% | 0.9% | |
Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.85B | 2.1B | 2.42B | 2.85B | 3.22B |
| Cost of Revenue | 470.52M | 503.02M | 532.06M | 580.24M | 736.83M |
| Gross Profit | 1.38B | 1.59B | 1.89B | 2.27B | 2.48B |
| Gross Margin | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% |
| Research & Development | 628.79M | 649.61M | 746.77M | 747.18M | 921.93M |
| Selling, General & Admin | 759.4M | 823.2M | 892.4M | 1.01B | 1.28B |
| Operating Expenses | 1.46B | 1.43B | 1.7B | 1.79B | 1.95B |
| Depreciation & Amortization | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M |
| EBITDA | 47.43M | 265.36M | 306.77M | 650.53M | 572.94M |
| EBITDA Margin | 2.6% | 12.7% | 12.7% | 22.8% | 17.8% |
| Operating Income | (82.34M) | 160.97M | 185.77M | 484.21M | 533.48M |
| Operating Margin | -4.5% | 7.7% | 7.7% | 17.0% | 16.6% |
| Interest Income | 10.48M | 18.03M | 58.34M | 74.88M | 74.9M |
| Interest Expense | 15.34M | 15.97M | 17.34M | 12.67M | 10.9M |
| Other Income / Expenses | 6.99M | (11.4M) | 2.79M | 57.55M | (51M) |
| Income Before Tax | (75.35M) | 149.58M | 188.56M | 541.76M | 482.48M |
| Pre-Tax Margin | -4.1% | 7.1% | 7.8% | 19.0% | 15.0% |
| Income Tax Expense | (11.27M) | 8.02M | 20.92M | 114.9M | 133.58M |
| Net Income | (64.08M) | 141.56M | 167.65M | 426.86M | 348.9M |
| Net Margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| EPS (Basic) | (0.35) | 0.76 | 0.89 | 2.25 | 1.82 |
| EPS (Diluted) | (0.35) | 0.75 | 0.88 | 2.21 | 1.80 |
| Weighted Avg Shares | 182.85M | 185.27M | 187.83M | 190.03M | 191.79M |
| Weighted Avg Shares (Diluted) | 182.85M | 188.96M | 191.6M | 196.71M | 197.39M |
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Intrinsic Alpha fair value
Locked
Current Price
$61.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.